<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335436</url>
  </required_header>
  <id_info>
    <org_study_id>171688</org_study_id>
    <nct_id>NCT03335436</nct_id>
  </id_info>
  <brief_title>Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial of Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a perioperative course of gabapentin in
      parturients on buprenorphine maintenance would improve analgesia after elective cesarean
      delivery (CD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many strategies have been suggested to improve post-CD pain management in parturients on
      buprenorphine. While effective pain relief can be achieved, women maintained on buprenorphine
      during pregnancy have been shown to require up to 50% more opioids after CD compared to women
      with opioid use disorder not on a maintenance regimen. The perioperative use of gabapentin
      has been shown to reduce pain scores and opioid consumption following a variety of surgeries,
      ranging from cardiac bypass to total abdominal hysterectomy. The purpose of this study is to
      determine whether a perioperative course of gabapentin in parturients on buprenorphine
      maintenance would improve analgesia after elective CD.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid use 24 hours after cesarean delivery</measure>
    <time_frame>24 hours after cesarean delivery</time_frame>
    <description>Total opioid use tallied in morphine milligram equivalents at 24 hours after cesarean delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total opioid use at time of hospital discharge after cesarean delivery</measure>
    <time_frame>From the end of cesarean delivery to the time of hospital discharge after cesarean delivery, approximately 4 days</time_frame>
    <description>Total opioid use tallied in morphine milligram equivalents from the end cesarean delivery to the time of hospital discharge after cesarean delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 4 hours post-partum</measure>
    <time_frame>4 hours post-partum</time_frame>
    <description>Pain assessment using VAS at rest 4 hours post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 4 hours post-partum</measure>
    <time_frame>4 hours post-partum</time_frame>
    <description>Pain assessment using VAS at movement 4 hours post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 24 hours post-partum</measure>
    <time_frame>24 hours post-partum</time_frame>
    <description>Pain assessment using VAS at rest 24 hours post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 24 hours post-partum</measure>
    <time_frame>24 hours post-partum</time_frame>
    <description>Pain assessment using VAS at movement 24 hours post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 48 hours post-partum</measure>
    <time_frame>48 hours post-partum</time_frame>
    <description>Pain assessment using VAS at rest 48 hours post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 48 hours post-partum</measure>
    <time_frame>48 hours post-partum</time_frame>
    <description>Pain assessment using VAS at movement 48 hours post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at rest 30 days post-partum</measure>
    <time_frame>30 days post-partum</time_frame>
    <description>Pain assessment using VAS at rest 30 days post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using 11-point Visual/Verbal Analog (VAS) at movement 30 days post-partum</measure>
    <time_frame>30 days post-partum</time_frame>
    <description>Pain assessment using VAS at movement 30 days post-partum when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of persistent pain</measure>
    <time_frame>30 days post-partum</time_frame>
    <description>Presence of persistent pain defined as pain score greater than baseline at 30 days post-partum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to normal daily function</measure>
    <time_frame>30 days post-partum</time_frame>
    <description>Return to normal daily function assessed with the Veterans RAND 12-item questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cesarean Delivery</condition>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton, term pregnancy

          -  currently on buprenorphine maintenance therapy

          -  scheduled for elective CD under spinal anesthesia

        Exclusion Criteria:

          -  use illicit drugs or relapse during the last trimester of pregnancy

          -  positive drug screen at the time of delivery

          -  allergies to any medications used in the study

          -  taking prescribed gabapentin at the time of admission for CD

          -  contraindications to neuraxial anesthesia or require general anesthesia for CD

          -  designated ASA physical status 4 or above
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holly B Ende, M.D,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Holly Ende</investigator_full_name>
    <investigator_title>Asst Professor</investigator_title>
  </responsible_party>
  <keyword>buprenorphine maintenance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

